300 related articles for article (PubMed ID: 20467365)
21. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
[No Abstract] [Full Text] [Related]
22. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
Bartalena L
Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
[TBL] [Abstract][Full Text] [Related]
23. Novel immunomodulating agents for Graves orbitopathy.
Bartalena L; Lai A; Compri E; Marcocci C; Tanda ML
Ophthalmic Plast Reconstr Surg; 2008; 24(4):251-6. PubMed ID: 18645425
[No Abstract] [Full Text] [Related]
24. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
[TBL] [Abstract][Full Text] [Related]
25. [Graves' orbitopathy].
Balázs C
Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for Graves' ophthalmopathy.
Salvi M
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
[TBL] [Abstract][Full Text] [Related]
27. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
28. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
29. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy].
Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H
Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632
[TBL] [Abstract][Full Text] [Related]
30. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
31. The role of somatostatin analogs in the management of Graves' ophthalmopathy.
Bartalena L; Tanda ML; Piantanida E; Lai A
J Endocrinol Invest; 2003; 26(8 Suppl):109-13. PubMed ID: 15233224
[No Abstract] [Full Text] [Related]
32. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
33. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
[TBL] [Abstract][Full Text] [Related]
34. Surgical treatment of globe subluxation in the active phase of the myogenic type of Graves orbitopathy: case reports.
Eing F; Cruz AA
Arq Bras Oftalmol; 2012; 75(2):131-3. PubMed ID: 22760806
[TBL] [Abstract][Full Text] [Related]
35. [Management of Graves' ophthalmopathy].
Schalin-Jäntti C
Duodecim; 2010; 126(20):2431-7. PubMed ID: 21125757
[TBL] [Abstract][Full Text] [Related]
36. [Somatostatin analogs].
Krysiak R; Okopień B; Herman ZS
Pol Arch Med Wewn; 2006 Oct; 116(4):988-97. PubMed ID: 18416302
[No Abstract] [Full Text] [Related]
37. Medical Treatment of Graves' Orbitopathy.
Salvi M; Campi I
Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263
[TBL] [Abstract][Full Text] [Related]
38. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM; Druce M; Ansari E
BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
[TBL] [Abstract][Full Text] [Related]
39. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
40. Graves'-like orbitopathy in a patient with chronic autoimmune pancreatitis.
Fonte R; Pirali B; Caramia V; Dionisio R; Lodigiani S; Sibilla L; Rotondi M; Chiovato L
Thyroid; 2011 Dec; 21(12):1389-92. PubMed ID: 22066480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
